- TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND
-
Disclosed is a series of tricyclic substituted piperidine dione compounds, and applications thereof in the preparation of medicines for treating diseases related to CRBN protein; specifically disclosed are the derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
- -
-
Paragraph 0131-0132
(2021/07/17)
-
- Enantioselective Ni-Catalyzed Electrochemical Synthesis of Biaryl Atropisomers
-
A scalable enantioselective nickel-catalyzed electrochemical reductive homocoupling of aryl bromides has been developed, affording enantioenriched axially chiral biaryls in good yield under mild conditions using electricity as a reductant in an undivided cell. Common metal reductants such as Mn or Zn powder resulted in significantly lower yields in the absence of electric current under otherwise identical conditions, underscoring the enhanced reactivity provided by the combination of transition metal catalysis and electrochemistry.
- Chen, Song,Chen, Yue-Gang,Gao, Pei-Sen,Liu, Dong,Ma, Hong-Xing,Mei, Tian-Sheng,Qiu, Hui,Shuai, Bin,Wang, Yun-Zhao
-
p. 9872 - 9878
(2020/06/27)
-
- Modular Assembly of Spirocarbocyclic Scaffolds through Pd0-Catalyzed Intermolecular Dearomatizing [2+2+1] Annulation of Bromonaphthols with Aryl Iodides and Alkynes
-
A novel palladium(0)-catalyzed dearomatizing [2+2+1] spiroannulation of 1-bromo-2-naphthols with aryl iodides and alkynes was developed for the rapid assembly of spiro[indene-1,1′-naphthalen]-2′-ones. This three-component cascade reaction was realized thr
- Zuo, Zhijun,Wang, Hui,Fan, Liangxin,Liu, Jingjing,Wang, Yaoyu,Luan, Xinjun
-
supporting information
p. 2767 - 2771
(2017/02/26)
-
- A scalable and expedient route to 1-Aza[6]helicene derivatives and its subsequent application to a chiral-relay asymmetric strategy
-
A rapid route to diversely functionalized 1-aza[6]helicenes has been achieved via the development of a copper-mediated cross-coupling reaction, followed by PtCl4-catalyzed cycloisomerization. Not only does this method allow access to these func
- Weimar, Marko,Correa Da Costa, Rosenildo,Lee, Fu-Howe,Fuchter, Matthew J.
-
supporting information
p. 1706 - 1709
(2013/06/27)
-
- SELECTIVE ESTROGEN RECEPTOR MODULATOR
-
The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 8; 9
(2010/04/27)
-
- Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety
-
Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation.
- Richardson, Timothy I.,Frank, Scott A.,Wang, Minmin,Clarke, Christian A.,Jones, Scott A.,Ying, Bai-Ping,Kohlman, Dan T.,Wallace, Owen B.,Shepherd, Timothy A.,Dally, Robert D.,Palkowitz, Alan D.,Geiser, Andrew G.,Bryant, Henry U.,Henck, Judith W.,Cohen, Ilene R.,Rudmann, Daniel G.,McCann, Denis J.,Coutant, David E.,Oldham, Samuel W.,Hummel, Conrad W.,Fong, Kin C.,Hinklin, Ronald,Lewis, George,Tian, Hongqi,Dodge, Jeffrey A.
-
p. 3544 - 3549
(2008/02/07)
-
- SELECTIVE ESTROGEN RECEPTOR MODULATORS
-
The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
- -
-
Page/Page column 17-18
(2010/02/13)
-
- A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats
-
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, respectively) and is a potent uterine
- Hummel, Conrad W.,Geiser, Andrew G.,Bryant, Henry U.,Cohen, Ilene R.,Dally, Robert D.,Fong, Kin Chiu,Frank, Scott A.,Hinklin, Ronald,Jones, Scott A.,Lewis, George,McCann, Denis J.,Rudmann, Daniel G.,Shepherd, Timothy A.,Tian, Hongqi,Wallace, Owen B.,Wang, Minmin,Wang, Yong,Dodge, Jeffrey A.
-
p. 6772 - 6775
(2007/10/03)
-
- SELECTIVE ESTROGEN RECEPTOR MODULATORS
-
The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
- -
-
Page/Page column 9-10
(2008/06/13)
-
- SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS
-
The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
- -
-
Page/Page column 12-13
(2008/06/13)
-
- SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP
-
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
- -
-
Page/Page column 11-12
(2008/06/13)
-
- Biphenyl compounds and their use as oestrogenic agents
-
Compounds of formula (I), wherein [X] represents aromatic carbocyclic rings (A) and (B), where R1, R2, R3, R4, R5, R6and R7are as defined in the description, salts thereof, a method and intermediates for preparing same, the use thereof as drugs, and pharmaceutical compositions containing same, are disclosed.
- -
-
-
- Biphenyl compounds and use thereof as oestrogenic agents
-
PCT No. PCT/FR97/00184 Sec. 371 Date Aug. 28, 1998 Sec. 102(e) Date Sep. 28, 1998 PCT Filed Jan. 30, 1997 PCT Pub. No. WO97/28116 PCT Pub. Date Aug. 7, 1997Compounds of formula (I), wherein [X] represents aromatic carbocyclic rings (A) and (B), where R1, R2, R3, R4, R5, R6 and R7 are as defined in the description, salts thereof, a method and intermediates for preparing same, the use thereof as drugs, and pharmaceutical compositions containing same, are disclosed.
- -
-
-